Olaparib monotherapy as primary treatment in unselected triple negative breast cancer
2020 · Annals of Oncology · 210 citations
https://doi.org/10.1016/j.annonc.2020.11.009
H
Hans Petter Eikesdal
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
97
Papers
1.8K
Citations
23
h-index
37
i10-index
Hans Petter Eikesdal is an academic researcher from Haukeland University Hospital. The author has contributed to research in topics: PI3K/AKT/mTOR signaling in cancer & BRCA gene mutations in cancer & PARP inhibition in cancer therapy. The author has an h-index of 23, co-authored 83 publications.
ORCID: 0000-0003-4086-0147Papers by this author
worksBRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study
2015 · European Journal of Human Genetics · 73 citations
https://doi.org/10.1038/ejhg.2015.196
PARP-inhibition reprograms macrophages toward an anti-tumor phenotype
2022 · Cell Reports · 52 citations
https://doi.org/10.1016/j.celrep.2022.111462
The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy
2014 · Expert Opinion on Pharmacotherapy · 50 citations
https://doi.org/10.1517/14656566.2014.885952
DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival
2022 · Breast Cancer Research · 32 citations
https://doi.org/10.1186/s13058-022-01537-9
Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development
2023 · Genome Medicine · 27 citations
https://doi.org/10.1186/s13073-023-01262-8
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat